Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Jun 18, 2023; 14(6): 443-457
Published online Jun 18, 2023. doi: 10.5312/wjo.v14.i6.443
Chondroitin sulfate and glucosamine combination in patients with knee and hip osteoarthritis: A long-term observational study in Russia
Alexander M Lila, Lyudmila I Alekseeva, Andrey A Baranov, Elena A Taskina, Natalya G Kashevarova, Natalia A Lapkina, Evgeny A Trofimov
Alexander M Lila, Director, Research Institute of Rheumatology Named after VA Nasonova, Moscow 115522, Moscow, Russia
Lyudmila I Alekseeva, Elena A Taskina, Natalya G Kashevarova, Bone and Joints Metabolic Diseases Laboratory, Research Institute of Rheumatology Named after VA Nasonova, Moscow 115522, Moscow, Russia
Andrey A Baranov, Natalia A Lapkina, Department of Therapy, Clinical Laboratory Diagnostics and Medical Biochemistry, Yaroslavl State Medical University, Yaroslavl 150000, Yaroslavl, Russia
Evgeny A Trofimov, Department of Therapy and Rheumatology, North-Western State Medical University named after I.I. Mechnikov, St. Petersburg 191015, St. Petersburg, Russia
Author contributions: Lila AM and Alekseeva LI were the guarantors and designed the study, and reviewed study protocol. Baranov AA, Taskina EA, Kashevarova NG, Lapkina NA, and Trofimov EA participated in the acquisition, analysis, and interpretation of the data. Alekseeva LI and Taskina EA drafted the initial manuscript; Lila AM, Baranov AA, Taskina EA, LapkinaNA, and Trofimov EA critically revised the article for important intellectual content.
Institutional review board statement: Intercollegiate Ethics Committee of the Russian Federation (protocol number 08/17 dated on September 14, 2017); Amendment 1 (protocol number 11/17 dated on December 14, 2017); Amendment 2 (protocol number 08/18 dated on September 20, 2018); and Bayer Therapeutic Review Committee (Protocol Review Committee meeting was held on June 14, 2017).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent for data collection prior to study enrollment.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement checklist of items, and the manuscript was prepared and revised according to the STROBE Statement checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Elena A Taskina, MD, PhD, Senior Researcher, Bone and Joints Metabolic Diseases Laboratory, Research Institute of Rheumatology named after VA Naso-nova, Kashirskoe av., 34/1, Moscow 115522, Moscow, Russia. elena.taskina.msk@gmail.com
Received: March 6, 2023
Peer-review started: March 6, 2023
First decision: March 24, 2023
Revised: April 19, 2023
Accepted: May 12, 2023
Article in press: May 12, 2023
Published online: June 18, 2023
Processing time: 104 Days and 10 Hours
Core Tip

Core Tip: Long-term 64-wk treatment by oral capsules of glucosamine hydrochloride 500 mg and chondroitin sulfate 400 mg three times a day for the first 3 wk, then twice daily, was associated with clinically significant improvements in all subscale scores (Pain, Symptoms, Function, and Quality of Life) of the Knee Injury and Osteoarthritis Outcome Score/Hip Disability and Osteoarthritis Outcome Score and a decreasing number of patients with knee and hip osteoarthritis receiving any non-steroidal anti-inflammatory drugs in real-world clinical practice. Incidence of drug-related adverse events was low, and their nature was consistent with known safety profile of glucosamine hydrochloride and chondroitin sulfate combination.